The U.S. House on Saturday passed a $1.9 trillion COVID-19 relief bill with language that might lead to 340B ceiling prices on some branded drugs being set lower than the drugs’ average manufacturer price (AMP).
The bill, H.R. 1319, was approved 219-212, with all Republicans and two Democrats opposed. “Now the bill moves to the United States Senate where I hope it will receive quick action,” President Biden said Sunday. “We have no time to waste.”
The U.S. House on Saturday passed a $1.9 trillion COVID-19 relief bill with language that might lead to 340B ceiling prices on some branded drugs being set lower than the drugs’ average manufacturer price (AMP).
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
